Re: NRGN
What looks so "crazy good" about it? They've got what appears to be less than a year of cash so you had better hope they either get some serious cash from a big partnership or otherwise get bought out.
Also, aplindore, the compound NRGN is primarily focusing on now in two indications (Parkinsons and RLS) was in-licensed from Wyeth. I find it hard to get excited about compounds in-licensed from other companies due to the mindset of, if it was such a good drug, why would the large pharmaceutical company give it up to a tiny biotech? There may be some examples of instances where these drugs have proven to be successful, but I would bet that the majority of the time this is not the case.
News 
Market Data 
Discover 
